Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Abstract

With high efficacy and manageable tolerability, zanubrutinib plus salvage chemotherapy may be a potential treatment option for R/R DLBCL. CAR-T cell therapy may be a priority strategy for these poor responders to BTKi-based treatment.